Siga (SIGA - Get Report) soared 159% early Wednesday after the micro-cap biotech claimed its lead drug became "the first drug ever to demonstrate 100% protection against human smallpox virus in a primate trial conducted at the federal Centers for Disease Control and Prevention.""This test in non-human primates is as close as anyone can get to the real thing because there has not been any natural occurrence of smallpox since 1977," Siga said. The New York-based company said the Department of Homeland Security has designated smallpox a "material threat" to national security, so Siga-246 "will be eligible for purchase for the Strategic National Stockpile under Project Bioshield." Shares rose $3.13 to $5.10.
More from Stocks
General Motors Jumps After UAW Reaches Tentative Deal to End Month-Long Strike
GM shares jumps Wednesday after the United Auto Workers union said it had reached a tentative agreement to end a month-long strike at the country's biggest carmaker.
Dow Wavers as Trade War Worries, Weak Retail Sales Overshadow Strong Earnings
Stocks waver as investors divide their attention among strong third-quarter earnings and concerns over weak U.S. retail sales and the ongoing U.S.-China trade war.